Navigation Links
Oncolytics Biotech Inc. Collaborators to Present Preclinical Combination REOLYSIN(R) and Cisplatin Research at EORTC-NCI-AACR Annual Meeting
Date:10/22/2008

of Cancer (EORTC), the U.S. National Cancer Institute (NCI) and the American Association for Cancer Research (AACR).

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the implication of the materials presented at this meeting with respect to REOLYSIN(R), the Company's expectations related to the results of trials investigating delivery of REOLYSIN(R), and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN(R), uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 ... announced the addition of the report " ... " to their offering.      ... reviews basics of human genome variations, development ... large and small sequencers are described as ...
(Date:6/18/2013)... 2013   Lexicon Pharmaceuticals, Inc. (Nasdaq: ... on discovering breakthrough treatments for human disease, announced ... the company as its vice president of marketing, ... commercial experience to Lexicon, including both pre-launch planning ... areas. Mr. Northcott has held commercial ...
(Date:6/18/2013)... DUBLIN , June 18, 2013 ... Markets ( http://www.researchandmarkets.com/research/cmbgcv/north_american ) has announced ... American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes ... Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, ... to 2017" report to their ...
(Date:6/18/2013)... June 18, 2013 Inflamax Research ... of Concept and Phase I-IV clinical trials, announced ... with Northern Air Environmental Technologies (NAET), a specialty ... deployment, monitoring, and servicing of mobile Environmental Exposure ... clinical trials. , Inflamax Research ...
Breaking Biology Technology:DNA Sequencing: Technologies, Markets and Companies - 2013 Report 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 2John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations 3North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 2North American Nuclear Medicine/Radiopharmaceuticals & Stable Isotopes Market - Forecast to 2017 3Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 2Inflamax Research Inc. Enters Strategic Partnership with Northern Air Environmental Technologies Inc. 3
... CLAREMONT, Calif.*, May 19 /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products ... Beijing Hai Xin Science and Technology Co., Ltd.,("Hai ... This,May, the Board Chairman of Hai Xin, Mr. ... Kiwa,s Beijing headquarters., Hai Xin is a ...
... Digital Radiography, PACS and Practice Management Software Adds ... Philips Ultrasound ... Eklin Medical Systems, a,leading developer of digital radiography (DR), ... (VIA(TM)) for,veterinary care practices, announced it has completed its ...
... May 19 Replikins Ltd. has found that ... found in the,trypanosomes that are the infectious agents ... in fact the highest replikin concentrations observed to,date ... also found that these,concentrations cycle over several years., ...
Cached Biology Technology:Kiwa Bio-Tech in Collaboration Discussions with Beijing Hai Xin Science and Technology Co., Ltd. 2Kiwa Bio-Tech in Collaboration Discussions with Beijing Hai Xin Science and Technology Co., Ltd. 3Eklin Announces Acquisition of Ultrasource, Inc. 2Eklin Announces Acquisition of Ultrasource, Inc. 3Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes 2
(Date:6/18/2013)... of DNA and this modification can occur in ... now, scientists believed that this epigenetic phenomenon actively ... team of researchers from the University of Geneva ... at the Faculty of Medicine, reveals that this ... methylation may play both a passive and active ...
(Date:6/17/2013)... patients with severe brain infections in Vietnam. Further research ... for the symptoms of disease. , The virus was ... patients with severe brain infections in the study, corresponding ... 122 patients with non-infectious brain disorders that were tested. ... are often fatal and patients who do survive, often ...
(Date:6/17/2013)... improving original foundations with more modern elements. Using this ... Kenneth P. Dietrich School of Arts and Sciences have ... delivery, gas storage, and gas transport more efficient and ... the latest issue of the Journal of the ... recent work builds upon Pitt Associate Professor of Chemistry ...
Breaking Biology News(10 mins):The secret of DNA methylation 2New virus isolated from patients with severe brain infections 2New virus isolated from patients with severe brain infections 3'Chemical architects' build materials with potential applications in drug delivery and gas storage 2
... 13, 2011   Fate Therapeutics, Inc. announced ... trial of ProHema (FT1050-enhanced umbilical cord blood) as ... adult patients with hematologic malignancies who have undergone ... at the 53rd annual American Society of Hematology ...
... least one person admits that the extreme heat in Texas this year ... a handmade torture chamber. ... about the heat, but from my viewpoint as a breeder, I love ... maximum mean highs of 107 degrees for weeks near Mansfield and 104 ...
... have found an explanation for how the intestinal tract ... prevent infection, offering a potential clue to the cause ... "The findings shed light on the complex balance ... Prof. Jennifer Gommerman, an Associate Professor in the Department ...
Cached Biology News:Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference 2Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference 3Fate Therapeutics Announces Promising Data From Phase 1b Study of ProHema at the 2011 American Society of Hematology Annual Conference 4Rose torture: severe heat in Texas yields better varieties for research 2Intestine crucial to function of immune cells, research shows 2Intestine crucial to function of immune cells, research shows 3
... Provides a buffered anti-freeze environment for ... Maintains a liquid, low viscosity solution at ... is necessary and sampling is convenient ... during long-term storage Protect enzyme conjugates ...
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
... The V-106 voice-coil scanning and ... where small samples have to be ... and high resolution. It provides superior ... leadscrew drives. The mechanics (X or ...
Improves spot morphology and DNA binding to the slide resulting in increased hybridization signal. ID Clarifier: Optimized spotting solution for use with SigmaScreen APS Coated Slides for Microarrays...
Biology Products: